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Background: The clinical outcome of hypertrophic cardiomyopathy patients is not only determined by the 
disease-causing mutation but influenced by a variety of disease modifiers. Here, we defined the role of the 
mutation location and the mutant protein dose of the troponin T mutations I79N, R94C and R278C. 
Methods and results: We determined myofilament function after troponin exchange in permeabilized single 
human cardiomyocytes as well as in cardiac patient samples harboring the R278C mutation. Notably, we found 
that a small dose of mutant protein is sufficient for the maximal effect on myofilament Ca2+-sensitivity for the 
I79N and R94C mutation while the mutation location determines the magnitude of this effect. While incorpo-
ration of I79N and R94C increased myofilament Ca2+-sensitivity, incorporation of R278C increased Ca2+- 
sensitivity at low and intermediate dose, while it decreased Ca2+-sensitivity at high dose. All three cTnT mutants 
showed reduced thin filament binding affinity, which coincided with a relatively low maximal exchange (50.5 ±
5.2%) of mutant troponin complex in cardiomyocytes. In accordance, 32.2 ± 4.0% mutant R278C was found in 
two patient samples which showed 50.0 ± 3.7% mutant mRNA. In accordance with studies that showed clinical 
variability in patients with the exact same mutation, we observed variability on the functional single cell level in 
patients with the R278C mutation. These differences in myofilament properties could not be explained by dif-
ferences in the amount of mutant protein. 
Conclusions: Using troponin exchange in single human cardiomyocytes, we show that TNNT2 mutation-induced 
changes in myofilament Ca2+-sensitivity depend on mutation location, while all mutants show reduced thin 
filament binding affinity. The specific mutation-effect observed for R278C could not be translated to myofila-
ment function of cardiomyocytes from patients, and is most likely explained by other (post)-translational 
troponin modifications. Overall, our studies illustrate that mutation location underlies variability in myofilament 
Ca2+-sensitivity, while only the R278C mutation shows a highly dose-dependent effect on myofilament function.   
1. Introduction 
Hypertrophic cardiomyopathy (HCM) is the most prevalent inherited 
heart disease affecting 1:500 to 1:200 individuals in the general popu-
lation [1,2]. Current genetic screening identifies a pathogenic gene 
variant (further referred to as mutation) in ~50–60% of all patients [3]. 
Despite improved genotyping, prediction of disease based on genotype is 
challenging as the HCM population shows large clinical variability. This 
is evident from large differences in disease onset and severity, even in 
individuals carrying the exact same mutation. There is thus no clear 
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genotype-phenotype relation as shown for mutations in the 3 most 
frequent affected sarcomere genes [4]. As the majority of genotype- 
positive individuals are heterozygous for a gene mutation, carrying 
one normal and one mutant allele, clinical heterogeneity may be 
explained by the abundance (dose) of the mutant protein. Although 50% 
of healthy and 50% of mutant protein would be expected with a het-
erozygous mutation, this ratio can change due to allelic expression being 
stochastic, which can result in variable expression levels of healthy and 
mutant protein [5,6]. Accordingly, 43% of mutant protein has been 
shown in human induced pluripotent stem cell-derived cardiomyocytes 
carrying the I79N mutation in the gene (TNNT2) encoding cardiac 
troponin T (cTnT) [7], whereas heterozygous Tnnc1-A8V mice only 
showed 21% of mutant protein [8]. Furthermore, mutant protein dose 
can be influenced by changes in protein stability and/or degradation. A 
mutant protein dose-dependent increase in myofilament Ca2+-sensi-
tivity was reported in a transgene (Tg) mouse model with a α-tropo-
myosin mutation [9]. Another study showed a dose-dependent effect of 
the Tnnt2 mutation R92Q on morphological and structural abnormal-
ities as well as hypertrophy markers in Tg mice [10]. 
In addition to mutant protein dose, location of the mutation in the 
gene may explain the degree of cardiac muscle dysfunction. A mutation 
location effect has been observed in a study comparing two mouse 
models with different Tnnt2 mutations, a missense and a truncation 
mutation, that differ in their degree of hypertrophy and fibrosis devel-
opment [11]. Furthermore, studies in transgenic mice found that the 
Tnnt2 mutation I79N increased Ca2+-sensitivity [12], whereas the 
R278C mutation did not [13]. Differences in Ca2+-sensitivity and Ca2+- 
binding affinity have also been demonstrated in a study comparing the 
mouse models for Tnnt2 I79N, F110I and R278C [14]. Similarly, in vitro 
studies using recombinant proteins have shown that the HCM-associated 
increase in Ca2+-sensitivity differs for different human TNNT2 muta-
tions incorporated into porcine fibers [15], strengthening the concept of 
mutation location as a disease modifier. 
Based on these previous studies, we hypothesize that the degree of 
myofilament dysfunction depends on both the mutant protein dose and 
mutation location. To test our hypothesis we make use of the troponin 
exchange method in human cardiomyocytes, which enables us to control 
the dose of mutant protein in single cardiac muscle cells and study the 
effects on myofilament Ca2+-sensitivity. We compared three pathogenic 
TNNT2 mutations I79N, R94C and R278C. Furthermore, we were able to 
characterize myofilament function in three human myectomy samples of 
patients carrying the R278C mutation, which enabled us to compare the 
effects of this specific mutation in the absence (exchange experiments) 
and presence (myectomy samples) of secondary disease remodeling. 
2. Methods 
2.1. Human cardiac samples 
Exchange experiments were performed in the human sample 2.114 
which had a high endogenous phosphorylation background and was 
obtained from the Sydney Heart Bank. HCM tissue samples from the 
interventricular septum of patients harboring the TNNT2 R278C muta-
tion were obtained during myectomy surgery to relieve LV outflow tract 
obstruction and collected by the Erasmus University Medical Center 
Rotterdam and the University of Florence. HCM samples from patients 
with other mutations and without a sarcomere mutation (sarcomere 
mutation-negative) were used as controls in our protein analyses studies 
(samples from Erasmus Medical Center and Sydney Heart Bank). Table 1 
provides an overview, including clinical characteristics, of all HCM 
samples used in this study. The samples 4.021, 5.033, 6.034, 7.012 and 
7.040 were used as non-failing controls for single cardiomyocyte mea-
surements and/or western blot analysis. They originate from the LV free 
wall of donor hearts without history of cardiac disease and were ob-
tained from the Sydney Heart Bank. Written informed consent was ob-
tained from each patient prior to myectomy and the study protocol was 
approved by the local medical ethics review committees. All samples 
were stored in liquid nitrogen until use. 
2.2. Cardiomyocyte force measurements 
Single cardiomyocytes were mechanically isolated from frozen car-
diac tissue and functional myofilament measurements performed as 
described previously [16]. Briefly, the membrane of isolated car-
diomyocytes was permeabilized with 0.5% Triton X-100 and single 
cardiomyocytes were attached to a force transducer and a motor needle. 
To determine the force‑calcium relation, the force development of the 
cell was measured at different calcium concentrations. Ca2+-sensitivity 
of myofilaments was determined as the [Ca2+] needed to achieve half- 
maximal force (EC50). The protocol was performed at 1.8 and 2.2 μm 
Table 1 
Clinical characteristics of HCM samples. Clinical characteristics of human HCM samples that were used in this study. Abbreviations: sarcomere mutation negative 
(SMN), interventricular septum (IVS), left atrial diameter (LAD), enddiastolic diameter (EDD), left ventricular outflow tract obstruction (LVOTO). FL, samples from 
Florence; SHB, explanted heart sample from Sydney Heart Bank.  
Sample 
ID 
Age (yrs, at 
myectomy) 
Sex Genotype IVS 
(mm) 
LAD 
(mm) 
EDD 
(mm) 
E/A 
ratio 
E/e’ 
ratio 
Diastolic dysfunction 
(stage) 
LVOTO 
(mmHg) 
HCM 173 58 M TNNT2 R278C 18 51 40 1.5 15.7 2 74 
HCM 175 61 M TNNT2 R278C 16 46 50 0.75 12.5 2 31 
HCM 234 72 M TNNT2 R278C 19 62 38 NA 20.8 2 or 3 96 
FL 1084 49 M TNNT2 R278C & MYBPC3 
T1095M 
NA NA NA NA NA NA NA 
FL 1097 60 F TNNT2 R278C NA NA NA NA NA NA NA 
FL 10112 73 F TNNT2 R278C & MYBPC3 
K814del 
NA NA NA NA NA NA NA 
HCM 132 15 F TNNT2 Gln272* 19 37 39 2.33 17.5 3 81 
SHB 
3166 
26 M TNNT2 K280N 37 NA NA NA NA NA NA 
HCM 109 71 F SMN 22 52 53 1.30 33.6 2 130 
HCM 168 46 M SMN 15 49 41 1.00 20.4 2 92 
HCM 222 68 M SMN 15 45 49 1.39 27.2 2 61 
HCM 169 52 M MYBPC3 2373insG 21 45 43 0.87 15.9 1 100 
HCM 204 30 M MYBPC3 2373insG 19 37 37 1.14 16.3 2 100 
HCM 219 44 F MYBPC3 2373insG 19 48 43 1.5 12.5 3 74 
HCM 163 64 F TNNI3 R145W 23 46 42 0.52 16.3 1 125 
HCM 236 29 M MYH7 T1377M 26 52 44 1.83 18.3 2 104 
HCM 246 25 M MYH7 R663C 28 34 NA NA NA NA 38  
* Indicates a truncation after the amino acid. 
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sarcomere length of the cell to determine length-dependent activation 
(LDA), which was measured as the difference in EC50 at both sarcomere 
lengths. Only cells with a maximal force >10 kN/m2 were included in 
the analysis to ensure good quality of the cells. 
2.3. Troponin exchange in cardiomyocytes 
Troponin exchange in permeabilized cardiomyocytes was performed 
as described previously [17]. The recombinant troponin complex was 
expressed and assembled as reported before [18]. The membrane- 
permeabilized cells of a highly phosphorylated human sample were 
incubated with non-phosphorylated recombinant troponin complex at 
the concentrations 0.01, 0.1 and 1.5 mg/ml, resembling a low, inter-
mediate and high mutant protein concentration, respectively. Func-
tional measurements after exchange were performed after incubation 
with protein kinase A (PKA) because the incorporated recombinant 
troponin complex was non-phosphorylated. The amount of troponin 
replacement was determined by phos-tag analysis of cardiac troponin I 
(cTnI) using the phosphorylation difference between the endogenous 
and the recombinant troponin complex, the former being highly phos-
phorylated and the latter being non-phosphorylated (example shown in 
Fig. 1B for the TNNT2 I79N mutation). The percentage of troponin 
replacement after exchange was quantified as the percentage of non- 
phosphorylated cardiac troponin I (cTnI) of the total non-, mono- and 
bis-phosphorylated cTnI levels. 
2.4. Co-sedimentation assay 
Thin filament co-sedimentation assays were carried out using rabbit 
skeletal muscle filamentous actin (F-actin), recombinant human tropo-
myosin (Tm), and recombinant human troponin complexes as previously 
described [19,20] with a few modifications. Recombinant human car-
diac tropomyosin was expressed with the N-terminal tag alanine-serine 
after the initiatior methione to mimic N-terminal acetylation [21]. Prior 
Fig. 1. (A) Exchange of endogenous troponin complex with different concentrations of recombinant WT and mutant complex harboring the mutations I79N, R94C 
and R278C. Exchange percentage was analyzed by phos-tag gel analysis. (B) Representative image of phos-tag gel analysis for exchange curves in (A). (C) Ymax and k 
represent parameters of the exponential plateau curve fit with the 95% confidence interval (please note that an upper limit of Ymax and a lower limit of k for R278C 
could not be determined), n = 2. (D-E) Co-sedimentation assay. (D) Quantification of thin filament co-sedimentation assay results. Vertical axis is the band intensity 
ratio of cardiac troponin I to tropomyosin. (E) Representative image of an SDS-PAGE gel (12%) containing thin filament co-sedimentation products for WT and 
mutant troponin complexes. Abbreviations: S, supernatant; P, pellet; WT, wild-type; Tm, tropomyosin; cTnT, cardiac troponin T; cTnI, cardiac troponin I; cTnC, 
cardiac troponin C; one-way ANOVA with Dunnett’s multiple comparisons test, *p < 0.05, **p < 0.01 compared to WT. n = 4 for each condition. 
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to performing the assay, Tm and troponin complexes were centrifuged to 
remove potential precipitates and the resultant supernatants were 
resolved on a denaturing gel to assess purity. Protein concentrations 
were determined using Pierce Coomassie Plus/Bradford assay (Thermo 
Fisher Scientific). F-actin, Tm, and troponin complexes were combined 
at a molar ratio of 7:1:1, respectively, into a final volume of 100 μl co- 
sed buffer (25 mM HEPES, 60 mM NaCl, 3 mM MgCl2, 0.5 mM EGTA, 
1 mM DTT, 0.5 mM CaCl2, 2 mM β-mercaptoethanol, pH 7.0) resulting 
in a final concentration of 20 μmol/l F-actin, 2.86 μmol/l Tm and 2.86 
μmol/l troponin complex. The samples were centrifuged for 30 min at 
120,000 × g in a TLA-100 rotor (Beckman Coulter) at 21 ◦C. The pellets 
(P) and supernatants (S) were subsequently diluted with reducing 
Laemmli buffer, boiled, and resolved on 12% SDS-PAGE gels. The pro-
teins were stained with Coomassie, destained, and imaged on an Odys-
sey IR system (LI-COR Biosciences) followed by densitometric 
quantification using Image Studio V5.2 (LI-COR Biosciences). 
2.5. Phosphorylation assays 
Tissue samples were homogenized to a concentration of 2.5 μg/μl, 
and 100 μl of the homogenate was incubated with 10 units of protein 
kinase A (PKA; Sigma, P5511) and 0.006 mM cAMP for 40 min at 25 ◦C. 
The phosphorylation level before and after PKA incubation was assessed 
with ProQ phosphostaining and phos-tag gel analysis of cTnI. Troponin 
complexes were incubated with 0.5 units of PKA/μg and incubated at 
room temperature for 1, 5, 10, 20, 40 and 60 min. The phosphorylation 
level of cTnI was determined with phos-tag gel analysis. 
2.6. Protein analysis 
2.6.1. Protein phosphorylation 
Non-, mono- and bis-phosphorylated forms of cTnI (Pierce, MA1- 
22700) were quantified by phos-tag gel analysis as described previ-
ously [22]. It was used to assess the percentage of troponin replacement 
after exchange and to assess the cTnI phosphorylation level of human 
cardiac tissue samples. 
2.6.2. Protein levels 
Whole tissue lysates were prepared to determine troponin protein 
levels. Therefore, pulverized frozen tissue was homogenized in 40 μl/mg 
tissue 1× reducing sample buffer (106 mM Tris-HCl, 141 mM Tris-base, 
2% lithium dodecyl sulfate (LDS), 10% glycerol, 0.51 mM EDTA, 0.22 
mM SERVA Blue G250, 0.18 mM Phenol Red, 100 mM DTT) using a glass 
tissue grinder. Proteins were denatured by heating to 99 ◦C for 5 min and 
debris was removed by centrifugation at maximum speed for 10 min in a 
microcentrifuge (Sigma, 1–15 K). 
For analysis of troponin protein levels by Western blot, 5 μg of pro-
tein were separated on a 4–15% TGX gradient-gel (Biorad) and trans-
ferred to a polyvinylidene difluoride membrane. Site-specific antibodies 
directed to cTnT (ab10214, Abcam), cTnT (T6277, Sigma-Aldrich), cTnT 
(ab8295, Abcam), cTnI (ab10231, Abcam), cardiac Troponin C (cTnC, 
sc48347, Santa Cruz) and α-actinin (A7811, Sigma-Aldrich) were used 
to detect the proteins which were visualized with an enhanced chem-
iluminescence detection kit (Amersham) and scanned with Amersham 
Imager 600. Protein levels were determined by densitometric analysis. 
Protein levels were normalized to α-actinin or cTnI when appropriate. 
Equal loading of troponin complexes was verified with Imperial 
protein stain (Thermo Scientific). 
2.6.3. Mass spectrometry to determine mutant protein dose in human tissue 
samples 
Whole tissue lysates were run on 13% SDS gels to achieve a good 
separation of the cTnT and the actin band. Thereto approximately 15 μg 
of protein were loaded for each sample. The gel was stained with coo-
massie to visualize the protein bands and the cTnT band was cut out of 
the gel. 
Subsequently, a wash buffer (50% aqueous acetonitrile with 50 mM 
ammonium bicarbonate) was used to de-stain cut gel bands. De-stained 
gel bands were then cut into ~1 mm pieces and shrunk by incubation 
with acetonitrile at 37 ◦C for 10 min. Gel pieces were further dried in 
SpeedVac (Thermo Fisher Scientific, Waltham, MA). A digestion buffer 
(10% aqueous acetonitrile with 50 mM ammonium bicarbonate) was 
added to rehydrate the gel pieces. Reductive alkylation of cysteine was 
carried out by mixing with 1,4-dithiothreitol (DTT, Sigma-Aldrich, 
catalog #: 11583786001, St. Louis, MO) at 37 ◦C for 10 min followed 
by mixing with iodoacetamide (IAA, Sigma-Aldrich, catalog #: I1149, 
St. Louis, MO) at room temperature for 10 min. Afterwards, endopro-
teinase Glu-C (catalog number 90054, Thermo Fisher Scientific, Wal-
tham, MA) was added and the mixture was incubated at 37 ◦C overnight. 
The supernatant was collected and the digestion was quenched by 
addition of a 0.5% formic acid aqueous solution. After incubation at 37 
◦C for 10 min, the supernatant was collected. The gel pieces were dried 
by incubation with acetonitrile at 37 ◦C for 15 min and the supernatant 
was collected. The combined supernatant was dried in the SpeedVac. A 
series of calibration curve standards of varying mutant/wild-type (WT) 
cTnT ratios (0.05, 0.1, 0.2 and 1), but of a fixed total concentration of 20 
μM cTnT, was reductively alkylated with DTT and IAA with the same 
procedure as the in-gel digestion. After mixing with Glu-C and incuba-
tion at 37 ◦C overnight, the digestion reaction was quenched by addition 
of a 0.5% formic acid aqueous solution. The mixture was then dried in 
the SpeedVac. 
The dried peptides mixture was dissolved in a 0.1% formic acid 
aqueous solution and the mixture was injected to an Easy Nano-Liquid 
Chromatography (nLC) II system (Thermo Fisher Scientific, Waltham, 
MA) equipped with a 75 μm × 10 cm C18AQ analytical column (catalog 
# SC003, Thermo Fisher Scientific, Waltham, MA) and a 100 μm × 2 cm 
trap column (catalog # SC001, Thermo Fisher Scientific, Waltham, MA). 
Mobile phase composition is as follows – A: H2O with 0.1% formic acid; 
B: acetonitrile with 0.1% formic acid. The gradient profile is linear from 
1% B to 35% B in 90 min at 0.3 μl/min. The nLC was online coupled with 
a Hybrid Velos LTQ-Orbitrap Mass Spectrometer (Thermo Fisher Sci-
entific, Waltham, MA). Eluates from nLC were electrospray-ionized with 
a 2.2 kV spray voltage. For the initial peptide identification, precursor 
full mass scans (m/z 350–2000, mass resolution of 60,000 at m/z 400, 
automatic gain control – AGC target 1 × 106 ions and maximum ioni-
zation time 500 ms) were followed by data-dependent collisional- 
induced-dissociation (CID) MS2 of the top 9 most abundant precursor 
ions (AGC target 1 × 105 ions, maximum ionization time 100 ms, 
isolation window of 2 m/z, normalized collision energy NCE 35 and 
dynamic exclusion of 60 s). For quantification of percentage of mutant 
proteins, targeted FT scan (m/z 390–440, mass resolution of 60,000 at 
m/z 400, AGC target 1 × 106 ions, maximum ionization time 200 ms) 
were carried out in triplicates for each gel band samples and calibration 
curve standards.For initial peptide identification, the acquired Xcalibur. 
raw files were analyzed by Proteome Discoverer 1.4 with Sequest HT 
(Thermo Fisher Scientific) against a modified human proteome database 
with troponin T R278C mutant sequence. Variable modification of 
methionine oxidation and cysteine carboxymethylation were included. 
Mass tolerance was set with a precursor mass error of less than 5 ppm 
and MS2 fragment ion mass error of less than 0.8 Da. Peptides with 
sequence of NQKVSKTRGKAKVTGRWK (TnT WT 271–288, [M + 5H]5+
m/z 415.2498) and NQKVSKTCGKAKVTGRWK (TnT R278C MT 
271–288, C278 is carboxylated, [M + 5H]5+ m/z 416.0357) were 
identified as the R/C278 containing peptides with the highest S/N best 
suited for quantification. For quantification, the acquired Xcalibur.raw 
files with the targeted FT scan of m/z 390–440 were manually analyzed 
in the Xcalibur Qual Browser. Since the retention time (RT) of WT or 
mutant TnT 271–288 peptides overlaps, the MS signal over the RT with 
those MS (WT: m/z 415.2498; mutant: m/z 416.0357) signals were 
averaged and the ratio of mutant/WT MS signals calculated. A calibra-
tion curve was established with the above mentioned mutant/WT MS 
signals ratio and the actual mutant/WT concentration ratio. A linear 
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regression calibration curve was generated with R2 of 0.9964. 
2.7. RNA sequencing 
RNA was isolated using ISOLATE II RNA Mini Kit (Bioline) according 
to the manufacturer’s instructions with minor adjustments (10 min 
digestion using 20 μg proteinase K and a subsequent washing step using 
100% ethanol were added after the lysis step). Sample quality and 
quantity was assessed using the 2100 Bioanalyzer with a RNA 6000 Pico 
Kit (Agilent), and Qubit Flourometer with a HS RNA Assay (Thermo 
Fisher). After selecting the polyadenylated fraction of RNA, libraries 
were prepared using the NEXTflexTM Rapid RNA-seq Kit (Bioo Scien-
tific). Libraries were sequenced on the Nextseq500 Illumina platform, 
producing 75 bp long single end reads. Reads were aligned to the human 
reference genome GRCh37 using STAR v2.4.2a [23]. Picard’s AddOr-
ReplaceReadGroups v1.98 (http://broadinstitute.github.io/picard/) 
was used to add read groups to the BAM files, which were sorted with 
Sambamba v0.4.5 [24] and transcript abundances were quantified with 
HTSeq-count v0.6.1p1 [25] using the union mode. Subsequently, reads 
per kilobase million reads sequenced (RPKMs) were calculated with 
edgeR’s RPKM function [26]. The secondary structure of mRNAs were 
predicted using the RNAfold software, with the minimum free energy 
(MFE) and partition function option selected (URL: http://rna.tbi.univi 
e.ac.at/cgi-bin/RNAWebSuite/RNAfold.cgi) [27]. WT or mutant full- 
length human TNNT2 mRNA sequence corresponding to the adult- 
expressed isoform of cTnT (NCBI Reference Sequence: 
NM_001276347.2) was used for the prediction. 
2.8. Immunofluorescence 
Slides were thawed at RT for 20 min inside a closed a box. Tissue 
sections were washed with PBS-T, permeabilized with 0.25% PBS-Triton 
and blocked with 1% BSA and 10% donkey serum for 30 min. Primary 
antibodies for α-actinin (ACTN2, 14221-1-AP, Proteintech, dilution 
1:100) and cTnT (TNNT2 [1C11], ab8295, Abcam, dilution 1:250) were 
incubated overnight at 4 ◦C. Afterwards tissue sections were washed and 
incubated with suitable secondary Alexa fluor antibodies for 30 min. 
The sections were washed in PBS and mounted with Mowiol. Images 
where acquired with a Nikon A1 confocal microscope and analysis and 
quantifications were performed with FIJI software. 
2.9. Statistics 
Graphpad Prism v8 software was used for statistical analysis. Data 
were statistically analyzed using unpaired t-test, one-way ANOVA with 
Dunnett’s or Tukey’s multiple comparisons post hoc test or 2way- 
ANOVA when appropriate. All values are shown as mean ± standard 
error of the mean. A p-value ≤0.05 was considered as significantly 
different. 
3. Results 
3.1. Lower thin filament-binding affinity of mutant compared to WT 
troponin complex 
We performed troponin exchange in permeabilized human car-
diomyocytes to test the direct effect of mutation location and mutant 
protein dose on myofilament function. Therefore we used the HCM- 
causing troponin T mutations I79N, R94C and R278C. To analyze 
their ability to incorporate into the myofilaments and to determine the 
required complex concentration for a low, intermediate and high protein 
dose, we exchanged endogenous troponin with different concentrations 
of recombinant WT and mutant troponin complex. All complexes 
incorporated to a similar degree (Fig. 1A, C), with a maximum 
incorporation (Ymax) of 47% for WT, 49% for I79N, 45% for R94C and 
50% for R278C. Dose dependency of incorporation appeared to be 
slightly different for the different complexes. WT and I79N showed 
almost maximal incorporation at very low concentrations, while R94C 
and R278C reached the maximal incorporation at higher concentrations 
(Fig. 1A), which is also illustrated by the difference in k representing the 
rate constant (kWT = 15.0, kI79N = 22.2, kR94C = 6.2 and kR278C = 3.1) 
(Fig. 1C). However, the variation is too large to assess whether the 
complexes exchange differently at low and intermediate dose. Addi-
tionally, we performed a co-sedimentation assay with the three com-
plexes to determine their binding affinity to isolated thin filaments. 
While we observed reduced binding affinity of all three mutants 
compared to WT, no differences were observed in thin filament binding 
affinity between the three mutants (Fig. 1D, E, Table S1). 
3.2. Mutation location determines degree of myofilament dysfunction 
Based on the obtained percentage of exchange at different concen-
trations of recombinant troponin complex we selected 0.01 mg/ml, 0.1 
mg/ml and 1.5 mg/ml for subsequent functional experiments, which are 
indicated as low, intermediate and high dose, respectively. Exchange of 
cTn complex containing the TNNT2 mutants were compared to cells 
exchanged with cTn complex containing WT recombinant cTnT (1.5 
mg/ml). To avoid that PKA-mediated cTnI phosphorylation differences 
may mask mutant-related changes in myofilament function, all func-
tional measurements were performed in troponin-exchanged cells after 
treatment with exogenous PKA. A time-dependent PKA phosphorylation 
assay of the isolated recombinant complexes confirmed that the cTnI 
phosphorylation level of the recombinant complex after 40 min of PKA 
incubation is comparable to that of non-failing donors (Fig. S1). There 
was no difference in PKA’s ability to phosphorylate the different 
troponin complexes (Fig. S1E). Moreover, to further minimalize an 
interfering effect of myofilament protein phosphorylation background, 
exchange with all 4 troponin complexes (WT and 3 mutants) were per-
formed in the same human sample (sample 2.114). Interestingly, we did 
not see a mutant protein dose effect for the I79N and R94C mutations 
(Fig. 2A, B, D, E; Table S2). For the R94C mutation, a significant increase 
in Ca2+-sensitivity was seen at low dose of mutant protein, which did not 
increase further when increasing the dose (Fig. 2E), indicating that the 
maximal increase in myofilament Ca2+-sensitivity was already achieved 
at low dose. A similar pattern with a dose-independent trend to 
increased Ca2+-sensitivity (not significant) was observed for I79N 
(Fig. 2D). The magnitude of the increase in Ca2+-sensitivity is deter-
mined by the mutation location. We found that R94C increases Ca2+- 
sensitivity to a larger extent than I79N, depicted by the larger curve shift 
of R94C compared to I79N (Fig. 2G). 
Interestingly, we observed strikingly different results for the R278C 
complex. While the low and intermediate dose led to an increase in 
Ca2+-sensitivity to a similar level as R94C, we observed significantly 
decreased Ca2+-sensitivity for the high dose (Fig. 2C, F; Table S2). This is 
also demonstrated by the large difference in EC50 at low and high dose 
(Fig. 2F). In several exchange experiments we were able to determine 
the exchange efficiency in the remaining cell suspension after functional 
measurements of single cardiomyocytes. In Fig. 2I we plotted myofila-
ment Ca2+-sensitivity data relative to the troponin exchange efficiency 
obtained in experiments in which we collected both data sets. This figure 
illustrates the mutation location-specific effects on EC50. 
LDA, the cellular analogue for the Frank-Starling mechanism of the 
heart, was assessed for all three mutations at low, intermediate and high 
dose of mutant protein (Fig. 3A-C, Table S3). The variability between 
cells was large and we did not observe differences in LDA for all three 
mutations compared to cardiomyocytes exchanged with wild-type 
troponin complex. Maximal force did not differ between the different 
mutations and mutant protein dosages (Fig. 3D-F, Table S4). 
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3.3. Expression of R278C at mRNA and protein level in human patient 
samples 
In patients, the percentage of mutant protein in the cell and its 
contribution to disease variability is unknown. We collected myocardial 
tissue from the interventricular septum of three obstructive HCM pa-
tients carrying the R278C mutation during myectomy surgery (HCM 
173, HCM 175 and HCM 234). In these tissues we performed protein 
analysis and functional measurements to investigate the variability in 
patients with the exact same mutation. 
Western blot analysis revealed a 5.20 ± 0.37 fold increase in total 
cTnT protein levels in the three human TNNT2-R278C mutant samples 
compared to donor tissue, sarcomere mutation-negative (SMN) samples, 
samples with a truncating MYBPC3 mutation and samples with missense 
mutations in genes other than TNNT2, when analyzed with the ab10214 
antibody (abcam) (Fig. 4A, B). Levels of cTnI and cTnC were not 
changed in the TNNT2-R278C samples compared to all other groups 
(Fig. 4C, D), implying that the presence of mutation R278C in TNNT2 
leads to elevated cTnT levels only. This deviation from the expected 
troponin stoichiometry of 1:1:1 for cTnT, cTnI and cTnC would be an 
unexpected unique finding. Therefore, we also determined the cTnT 
protein levels with the T6277 (Sigma) and the ab8295 (abcam) anti-
bodies to validate the results. Interestingly, the analysis revealed 
elevated levels of cTnT but with a smaller fold change of 2.09 ± 0.13 for 
the T6277 antibody (Fig. 4E) and unchanged levels of cTnT with the 
ab8295 antibody (Fig. 4F). Because of these divergent results, we 
determined whether the antibodies have the same affinity to recombi-
nant WT and R278C cTnT protein, or whether the mutation affects 
antibody binding. To do so, we performed western blot analysis on 
different amounts of recombinant WT and R278C troponin complex. For 
the two antibodies ab10214 and T6277 we found an approximately 2- 
fold increase of the cTnT/cTnI signal for the R278C compared to WT, 
whereas the ab8295 antibody showed an increased cTnT/cTnI signal 
only at low protein concentrations (Fig. S2A-B). This indicates that the 
R278C mutation influences antibody binding of all three antibodies, in a 
possibly protein concentration-dependent manner. We obtained 3 more 
human TNNT2-R278C samples from an Italian patient cohort and 
compared all available TNNT2-R278C samples to two patient samples 
with other TNNT2 mutations (Gln272* and K280N) and could show that 
the increased cTnT signal is specific for tissue samples harboring the 
R278C mutation (Fig. S2C). Based on these western blot analyses we 
cannot make a confident statement about troponin stoichiometry in the 
Fig. 2. (A-C) Force‑calcium relations after exchange with cTnT I79N (A), R94C (B) and R278C (C) complex at low, intermediate and high dose. (D-F) EC50 values 
after exchange with I79N (D), R94C (E) and R278C (F) at low, intermediate and high mutant protein dose. (G) Comparison of force‑calcium relation of the different 
mutants at high dose. (H) Change in EC50 (ΔEC50) of mutants at high dose compared to WT. (I) Relation of EC50 and exchange percentage defined in the same 
exchange experiments. In (I) n(I79N) = 2/2/2, n(R94C) = 2/1/1, n(R278C) = 3/1/1 for low/intermediate/high dose, respectively. 
*p < 0.05, **p < 0.01 compared to WT in (D-F); ****p < 0.0001 compared to I79N and R94C in H, one-way ANOVA with Dunnett’s (D-F) or Tukey’s (H) multiple 
comparisons test. 
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TNNT2 R278C samples. Consequently, we performed immunofluores-
cence (IF) for cTnT and α-actinin on a selection of the human samples (3 
TNNT2 R278C, 1 Donor, 2 SMN, 2 MYBPC32373insG and 2 missense 
mutation samples) to determine cTnT protein levels with a different 
method. Due to the poor performance of the ab10214 and T6277 anti-
bodies in IF, we only used the ab8295 (abcam) antibody for the stain-
ings. In contrast to the western blot analysis of the ab10214 and T6277 
antibodies but in line with the results from the ab8295 antibody, IF did 
not show a significant difference in cTnT protein levels compared to the 
non-failing donor sample (p = 0.0777, Fig. 5A-B). Overall, our data show 
that the R278C mutation alters cTnT antibody-binding, and cannot be 
used to determine cTnT protein levels. 
We further performed RNA sequencing and mass spectrometry on 
two HCM tissue samples with the R278C mutation to assess the per-
centage of the mutant cTnT-R278C mRNA and protein levels in the 
samples. While TNNT2-R278C mRNA levels were close to 50%, the 
levels of mutant protein were 36% in HCM 173 and 28% in HCM 175 
(please note that we were not able to define levels in HCM 234 upon 
several attempts) (Fig. 5C and Fig. S3). This supports the results from the 
IF analysis that do not show elevated total cTnT levels in the TNNT2- 
R278C tissues. 
3.4. R278C mutant human samples differ on a functional level 
We compared myofilament function of the three patient samples in 
isolated membrane-permeabilized cardiomyocytes. While the difference 
in percentage of mutant protein was only slightly different between 
HCM 173 (36%) and HCM 175 (28%), the direction of the change in 
Ca2+-sensitivity compared to non-failing donors was opposite in these 
samples, showing a trend to an increase and a decrease, respectively 
(Figs. 6A-B, Table S5). HCM 234 shows a significant increase in Ca2+- 
sensitivity compared to donor samples (Fig. 6C, Table S5). Analysis of 
cTnI phosphorylation revealed reduced levels of phosphorylation in all 
three patient samples compared to donors, shown by lower levels of the 
highly phosphorylated 2P band and increased levels of the 1P and 0P 
bands (Fig. 6G-H). The lowest level of cTnI phosphorylation was 
observed in HCM 234. Since it is well-known that reduced cTnI phos-
phorylation increases myofilament Ca2+-sensitivity [16], we repeated 
the functional measurements after incubation with PKA to increase cTnI 
phosphorylation in HCM samples to levels observed in non-failing donor 
samples. First of all we determined with a phosphorylation assay if cTnI 
is still PKA responsive in these patients. As seen in Fig. 6G-H, cTnI 
phosphorylation increases after treatment with PKA in the TNNT2 
mutant samples, indicating that PKA-mediated phosphorylation of cTnI 
is not hampered by the presence of the TNNT2 mutation. Accordingly, 
PKA treatment of isolated cardiomyocytes decreases myofilament cal-
cium sensitivity significantly in HCM 173 and with a strong trend in 
HCM 234 (Fig. 6D-F, Table S5). In line with these results, we observed a 
blunted LDA in all three patient samples compared to donor, but 
detected a statistically significant difference only for HCM 173 (Fig. 6I- 
K, Table S6). LDA was enhanced only in HCM 173 after PKA-mediated 
phosphorylation of cTnI (Fig. 6L-N, Table S6). 
Overall, our data suggest that perturbations in myofilament function 
in samples harboring the R278C mutation can be corrected to values that 
are seen in non-failing samples by PKA treatment. 
4. Discussion 
In this study we investigated the mutation location and mutant 
protein dose effect of three HCM-causing TNNT2 mutations. We pro-
posed that the mutation location and mutant protein dose are potential 
disease modifiers via specific changes in myofilament function. While 
Fig. 3. (A), (B) and (C) show length-dependent activation after exchange with cTnT I79N, R94C and R278C, respectively. (D), (E) and (F) show maximal force 
development after exchange with cTnT I79N, R94C and R278C, respectively. Low, intermediate and high mutant protein dose are depicted for each mutation 
compared to WT. n(WT) = 11, n(I79N) = 7/6/9, n(R94C) = 7/3/5, n(R278C) = 6/5/4 for low/intermediate/high dose, respectively. 
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Fig. 4. (A) shows representative western blot images of troponin protein levels in the three human samples harboring the TNNT2 R278C mutation compared to 
control and other HCM patient samples with the cardiac troponin T (cTnT) antibodies ab10214, T6277 and ab8295. cTnT protein levels with the ab10214 antibody 
are quantified in (B). (C) shows quantified protein levels of cardiac troponin I (cTnI) and (D) of cardiac troponin C (cTnC). (E) displays quantified cTnT protein levels 
with the antibody T6277 and (F) with the antibody ab8295. Every dot represents the average of 2 data points per sample in (B), (E) and (F) and the average of 4 data 
points in (C) and (D). Data is normalized to Donor which is set to 1. ****p < 0.0001 compared to WT, one-way ANOVA with Dunnett’s multiple comparisons test. 
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Fig. 5. (A) Representative immunofluorescence images of human cardiac tissue stained for cardiac troponin T (cTnT), α-actinin and nuclei. (B) Quantified intensity 
of cTnT staining normalized to α-actinin staining. Every dot represents one sample and is an average of 3 images. (C) shows the content of mutant cTnT mRNA and 
protein in the human tissue samples determined by RNA sequencing and mass spectrometry. 
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our exchange experiments show a more important role for the mutation 
location than for the mutant protein dose for mutations I79N and R94C, 
the functional consequences of R278C are highly dose-dependent. 
4.1. Mutant protein dose effect is mutation-specific 
HCM mutations in thin filament proteins such as cTnT have been 
associated with an increase in myofilament Ca2+-sensitivity [28,29] and 
blunted length-dependent myofilament activation [28]. Impaired LDA 
was normalized to values in non-failing donor cardiomyocytes by 
reducing the percentage of mutant cTnT to 22% [28]. In the present 
study, we show that a relatively low dose of mutant cTnT protein is 
sufficient to increase myofilament Ca2+-sensitivity, which was siginifi-
cant for R94C, though the magnitude is dependent on mutation location 
(Fig. 2). 
At low, intermediate and high dose of mutant protein we did not 
observe differences in LDA (Fig. 3). R94C led to an increase in myofil-
ament Ca2+-sensitivity independent of dose and also I79N showed a 
strong trend to increased dose-independent myofilament Ca2+-sensi-
tivity, with R94C having an even stronger effect than I79N. The Ca2+- 
sensitizing effect of I79N has been described previously [12,29,30], and 
also for R94C a Ca2+-sensitizing effect and hypercontractility has been 
predicted [31]. In our study, a very low dose of mutant protein results 
already in the maximal shift in myofilament Ca2+-sensitivity (Fig. 2I). In 
contrast to our study in human cardiomyocytes, the R92Q mutation 
showed a dose-dependent effect on atrial mass, hypertrophic markers 
and structural abnormalities in a Tg mouse model [10]. Unlike the direct 
mutation effects that we studied in single permeabilized cardiomyocyte, 
the dose-dependent changes in cardiac remodeling described in the Tg- 
mice may represent secondary changes and may not be solely due to the 
direct mutation dose effect. 
Several studies in animal models and patients have also described 
that individuals with two disease-causing mutations show earlier disease 
onset, more severe hypertrophy and a higher risk of sudden cardiac 
death [32–34]. Double mutations in the same gene, dependent on their 
location, might have an additive effect as described for two MYBPC3 
mutations [35]. Compound heterozygous or homozygous MYBPC3 
mutations have also been shown to cause severe cardiomyopathy which 
was lethal in the first few weeks after birth [36,37]. An additive muta-
tion dose effect has also been shown for double heterozygous mutations 
in two different genes like MYH7 and CSRP3 [38]. These studies indicate 
that the mutation dose effect might not always be in the dose of one 
gene, but rather in the combination of mutations in different genes that 
increase the cellular burden resulting in a more severe clinical outcome. 
In contrast to the findings with the I79N and R94C mutations, R278C 
shows a trend to increased Ca2+-sensitivity at low and a significant in-
crease at intermediate dose, while a high dose significantly decreased 
Ca2+-sensitivity (Fig. 2C, F, I). Conflicting results regarding this muta-
tion have been reported in literature, showing either a Ca2+-sensitiza-
tion or no effect on Ca2+-sensitivity [13,29]. Considering the findings of 
our study, the different reported effects on myofilament function could 
be explained by differences in mutant protein dose. The different 
behavior of the N-terminal TNNT2 mutations (I79N and R94C) and the 
C-terminal mutation R278C may also be explained by their interactions 
with other thin filament proteins, e.g. tropomyosin and cTnC as calcium 
binding to cTnC triggers conformational changes in troponin and 
tropomyosin that subsequently allow interactions between actin and 
myosin heads. The stoichiometry of 7:1:1 for actin, tropomyosin and 
troponin underlies the tight regulation of calcium-induced cross-bridge 
formation and myofilament force development. Molecular models based 
on crystal structures showed that the N-terminal region of cTnT (resi-
dues 87–150) is extremely elongated and interacts with both tropomy-
osin and 3 out of 7 actin subunits [39], and stabilizes tropomyosin- 
troponin binding to actin. As the cTnT N-terminus bridges over two 
tropomyosin strands [39], small amounts of mutant TNNT2 in this re-
gion may already exert a maximal effect on myofilament Ca2+-sensi-
tivity via propagation of the calcium-binding signal over the thin actin- 
filament. Furthermore, it has recently been shown that the C-terminus of 
cTnT, at which the R278C mutation is located, can directly interact with 
cTnC [19]. This cTnT-cTnC interaction may be altered by the presence of 
mutant R278C in a dose-dependent manner, and thereby differentially 
alter cTnC sensitivity to calcium. 
Interestingly, a divergent effect of a TNNT2 mutation has been re-
ported before. The introduction of the dilated cardiomyopathy (DCM)- 
causing TNNT2 mutation ΔK210 in reconstituted thin filaments led to 
decreased Ca2+-sensitivity when using WT and ΔK210 cTnT in a 50:50 
ratio, whereas it resulted in increased Ca2+-sensitivity when using 100% 
ΔK210 [40]. These findings indicate that dose-dependency of the 
functional defect might not be a common disease mechanism for all 
TNNT2 mutations but might depend on mutation location. Moreover, 
based on the elegant work by Davis and colleagues, who build proof for 
tension-mediated cardiomyocyte remodeling [41], the R278C mutation 
may trigger concentric remodeling (i.e. HCM phenotype) at low dose, 
and eccentric remodeling (i.e. DCM phenotype) at high protein dose. 
4.2. Mutation location determines myofilament alterations 
The differences between the mutations in this study could be due to 
mutation-specific changes in protein properties like structure or charge, 
that have differential effects on protein function by e.g. influencing their 
interaction with binding partners. In a study with MYH7 mutations, 
differences in disease severity have been proposed to depend on the 
mutation location due to their effect on different protein domains that 
might be of more or less importance for proper protein function [42]. 
Some of these mutations could be associated with either mild or severe 
disease phenotype [43,44]. Also for ACTC1 it has been described that 
the subdomain location of the mutation determines the alterations in 
protein properties. Mutations in one subdomain predominantly affected 
protein stability or polymerization, whereas mutations in other sub-
domains caused alterations in protein-protein interactions [45]. Vang 
et al. have shown in in vitro experiments that different HCM- and DCM- 
causing mutations in ACTC1 impair protein folding by the TRiC chap-
eronin complex resulting in inefficient incorporation into the myofila-
ment and aggregation of actin [46]. A similar mechanism could 
potentially explain the lower thin filament binding affinity of the TNNT2 
mutant complexes compared to WT (Fig. 1D). Pavadai et al. describe 
that the R94 residue, together with other charged residues, forms stable 
salt bridges that border hydrophobic patches leading to a very tight 
interaction of the cTnT fragment with residues 89–151 and tropomyosin 
[47]. Having an uncharged cysteine (C) instead of the positively charged 
arginine (R) at residue 94 may weaken the interaction of cTnT with 
tropomyosin and explain the reduced binding affinity of R94C to the 
thin filament. A similar mechanism may be true for the R278C mutation, 
which shows the same amino acid change. Accordingly, also the change 
from a non-polar isoleucine (I) to a polar asparagine (N) for the I79N 
mutation may potentially alter the interaction of cTnT with 
Fig. 6. (A-C) show myofilament Ca2+-sensitivity measured as EC50 for the human samples HCM 173, HCM 175 and HCM 234 carrying the TNNT2 R278C mutation 
compared to donor tissue. (D-F) show Ca2+-sensitivity measured as EC50 for the human samples HCM 173, HCM 175 and HCM 234 carrying the TNNT2 R278C 
mutation before and after normalizing cTnI phosphorylation by incubation with protein kinase A (PKA). (G) and (H) display the phosphorylation status of cardiac 
troponin I determined by phos-tag gel analysis before and after incubation with PKA. 0P represents non-phosphorylated cTnI, 1P single-phosphorylated cTnI and 2P 
double-phosphorylated cTnI. (G) shows the phos-tag gel image for the quantified data in (H). (I-K) Length-dependent activation of the human samples HCM 173, 
HCM 175 and HCM 234 compared to donor. (L-N) Length-dependent activation of the human samples HCM 173, HCM 175 and HCM 234 before and after PKA 
treatment. *p < 0.05, **p < 0.01, unpaired t-test. n(Donor) = 4, n(HCM 173) = 4/3, n(HCM 175) = 4/3, n(HCM 234) = 3/3 for with/without PKA, respectively. 
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tropomyosin. 
Differences in exchangeability into porcine skinned fibers of 
different mutant cTnT proteins was shown in a previous study, in which 
R92W, R94L or R130C showed reduced exchangeability compared to 
WT and other cTnT mutant proteins (A104V, E163R, S179F, E244D) 
[15]. This is in line with findings by Palm et al., who have shown that 
mutations within the residues 92–110 alter the interaction of cTnT with 
tropomyosin [48]. Furthermore, studies in Tg mice showed less efficient 
incorporation of mutant compared to WT cTnT. Tg-I79N lines expressed 
52% and 35% Tg-cTnT compared to 71% Tg-cTnT in the Tg-WT line 
[12]. Similar results have been reported for the Tg-cTnI mouse lines 
R145G and R145W that only showed 36% and 11% of mutant Tg-cTnI 
compared to 66% of Tg-cTnI in the Tg-WT line [49,50]. 
Overall, our study strengthens the notion that the degree of myofil-
ament dysfunction depends on mutation location, and that mutant cTnT 
protein reduces thin filament binding affinity of the troponin complex. 
4.3. Altered antibody binding affinity to cTnT-R278C 
Troponins function as part of a complex, which is closely linked with 
tropomyosin. It has been shown that mutations in one of the troponin 
units can affect the composition of the entire troponin complex. In a 
study of different DCM-causing troponin mutations it has been shown 
for a truncating mutation in TNNI3 and an amino acid deletion in TNNT2 
that the stoichiometry of the troponin complex was altered. In these 
DCM patient samples the mutation also affected the protein levels of its 
binding partners [51]. Although part of our western blot data suggests 
elevated cTnT levels in the TNNT2-R278C samples, we have shown in 
Fig. S2 that all cTnT antibodies show increased binding specifically to 
the mutant R278C compared to WT protein. Although the cTnT antibody 
epitope is more than 100 amino acids away from the mutation site, the 
amino acid change in the mutant protein is influencing antibody binding 
in western blot analysis. This, in combination with the ab8295 western 
blot and IF results, which did not show higher cTnT protein levels 
compared to donor (Fig. 5), suggest that there is no change in troponin 
stoichiometry in the HCM patient samples carrying the TNNT2-R278C 
mutation. 
This study shows that special care has to be taken when analyzing 
mutant proteins as antibody binding can be affected even under dena-
turing conditions. 
Our RNA analyses showed a ~50/50% ratio of WT and mutant 
mRNA in the TNNT2 R278C cardiac patient samples, while mass spec-
trometry revealed that the amount of mutant protein was less than 50%. 
This finding is in line with our in vitro data that show reduced binding of 
the mutant protein to the thin filament compared to WT and may explain 
the lower percentage of mutant protein in the human tissue. The pre-
dicted mRNA structures for WT and R278C mRNA differ, suggesting that 
R278C mRNA may indeed have different characteristics than WT mRNA 
(Fig. S4), which may affect its translation efficiency, resulting in lower 
protein levels of cTnT-R278C. Alternatively, it may be speculated that 
the turnover of WT cTnT protein is reduced, a mechanism which was 
recently proposed for MYBPC3 truncating mutations to maintain normal 
cMyBP-C levels and prevent haploinsufficiency [52]. Future research is 
warranted to investigate mechanisms underlying protein translation and 
turnover in order to define the role of both WT and mutant proteins in 
sarcomere homeostasis. 
4.4. Differences in myofilament function between human TNNT2 R278C 
samples do not correspond with mutant protein dose 
Interestingly, our human samples with the R278C mutation showed 
differences in myofilament Ca2+-sensitivity, while their clinical char-
acteristics were very similar (Table 1) and samples were all collected at 
the time of myectomy. HCM 173 showed a strong trend to increased 
myofilament Ca2+-sensitivity and HCM 234 showed a significant in-
crease in myofilament Ca2+-sensitivity compared to donor, whereas 
HCM 175 was not different. Based on the dose-dependent effect 
observed for the R278C mutation in our exchange experiments, i.e. high 
myofilament Ca2+-sensitivity at low dose, and low myofilament Ca2+- 
sensitivity at high mutant dose, mutant protein levels should be higher 
in the HCM 175 than in the HCM 173 sample. However, our mass 
spectrometry data showed a slightly lower mutant protein level in HCM 
175 (28%) than in HCM 173 (36%). 
A well-known modifier of Ca2+-sensitivity is PKA-mediated phos-
phorylation of cTnI [16]. While the level of cTnI phosphorylation was 
lower in all three samples compared to non-failing donor tissue, only 
HCM 173 and HCM 234 displayed increased Ca2+-sensitivity. Restoring 
phosphorylation of cTnI indeed decreased Ca2+-sensitivity significantly 
in HCM 173 and with a strong trend in HCM 234. Although PKA phos-
phorylation of cTnI is a major regulatory mechanism of myofilament 
Ca2+-sensitivity, there are many more post-translational protein modi-
fications that could potentially alter myofilament function. Also protein 
kinase C (PKC)-mediated phosphorylation can influence myofilament 
Ca2+-sensitivity and has been shown to decrease it [53]. Therefore, 
enhanced PKC activity may explain why Ca2+-sensitivity is not reduced 
in HCM 175 while the sample does show reduced phosphorylation of 
cTnI. 
Additionally, myofilament Ca2+-sensitivity could be influenced by a 
range of other factors, that are beyond the scope of this study. We can 
speculate that the extent of fibrosis, medication and the presence of 
comorbidities can influence myofilament function by altering post- 
translational modifications of myofilament proteins. 
Overall, our data illustrate that myofilament Ca2+-sensitivity 
measured at the time of myectomy in HCM samples harboring TNNT2 
mutations is highly diverse, and most likely reflect a complicated mix of 
translational and post-translational protein modifications. The latter is 
in line with our previous observations in HCM and DCM samples with 
thin filament gene mutations [28,51], and also matches previously re-
ported conflicting results on the R278C mutation. One study showed 
dramatically increased Ca2+-sensitivity [29], whereas another one 
described R278C as a rather benign mutation with no effect on Ca2+- 
sensitivity [13]. 
5. Study limitations 
This study gives new insight into the effect of mutant protein dose 
and location of TNNT2 mutations on human myofilament function. It is a 
limitation of the study that we only assessed two N-terminal mutations 
and one C-terminal mutation, which all show differences on a functional 
level. To make a more general statement on the effect of mutations in 
certain cTnT domains, additional mutation locations have to be inves-
tigated. Furthermore, our study shows that isolated mutation effects are 
not directly translatable to the human situation, since several other 
disease modifying factors can influence the impact of the mutant protein 
on the cell and lead to differences in the functional state of the car-
diomyocytes between patients with the same mutation. 
6. Conclusion 
From our exchange experiments we can conclude that mutant pro-
tein dose-dependency may be relevant only for certain TNNT2 muta-
tions. Based on our experiments, this may be true for mutations located 
in the C-terminal domain that interacts with other troponin subunits. 
Our studies show that a relatively small dose of mutant protein is suf-
ficient to exert the maximal effect on myofilament Ca2+-sensitivity for 
the I79N and R94C mutation, while the mutation location determines 
the magnitude of this effect. This could be explained by the interaction 
of troponin with tropomyosin which is involved in the regulation of 
cooperativity of thin filament activation. Our study emphasizes that care 
has to be taken when analyzing mutant proteins as single amino acid 
changes can alter antibody binding even under denaturing conditions. 
The ‘classical’ view of the HCM-related myofilament Ca2+-sensitization 
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clearly is too simplified, as our study shows that thin filament-based 
HCM pathology involves additional levels of complexity including 
sarcomere homeostasis and mutation-specific effects. 
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